Investor Centre
Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
3.85 GBX
Volume:
120,989
Market Capitalisation (m)
£10.58
2022 Interim Results Presentation
09 - December - 2022
Latest corporate presentation following publication of the interim results for 2022-23.
Stalicla Licensing Deal
10 - October - 2022Evgen Pharma has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla
Evgen InvestorMeet - Interim Results 2022-23
09 - December - 2022CEO Dr Huw Jones and CFO Richard Moulson provide an update following publication of the interim results for 2022-23.
| Company | Analyst |
|---|---|
| finnCap | Mark Brewer |
Major Shareholder
| Current Stakeholder | Number of shares | Percentage holding |
|---|---|---|
| J. R. Kight | 33,100,000 | 12.0% |
| AXA Framlington | 23,848,884 | 8.7% |
| Octopus Investments | 21,875,000 | 8.0% |
| SPARK Impact | 16,186,446 | 5.9% |
| Seneca Investment Managers | 14,932,071 | 5.4% |
| Chelverton Asset Management | 12,500,000 | 4.5% |
| RAB Capital | 8,750,000 | 3.2% |
| Newlands Capital | 8,314,815 | 3.0% |
The number of ordinary shares in issue is 274,888,117 all of which are in public hands. The Company does not hold any shares in Treasury.
